Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
about
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerDefinitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionationPhase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II studyA Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung CancerThe prognostic impact of supraclavicular lymph node in N3-IIIB stage non-small cell lung cancer patients treated with definitive concurrent chemo-radiotherapy.A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer.Concurrent chemoradiotherapy with tomotherapy in locally advanced Non-Small Cell Lung Cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimenPhase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancerPemetrexed for the treatment of non-small-cell lung cancer.Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and LeukemiRandomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancerStandard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factoRecent advances in combined modality therapyAdding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerSpleen Volume Variation in Patients with Locally Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemo-Radiotherapy.Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer.C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expressionEffects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancerPooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)?Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancerQuality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical TrialLong-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer.Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancerDose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer.High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancePhase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer.Did dose escalated radiotherapy in stage III non-small cell lung cancer improve overall survival?Therapeutic management options for stage III non-small cell lung cancer.A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancerThe use of proton-beam therapy in the treatment of non-small-cell lung cancer.
P2860
Q26827571-B4256830-04E6-4610-B58E-98D963CB2D03Q27027626-09F32B87-DEF6-45BB-8282-BA7A9D036C9AQ33385378-FE5EF8D1-8B61-4831-AAD0-983D6C0B7ED8Q33415544-EA368755-99F5-40E9-A2A7-B966BB8B9FA5Q33786722-D7209E2B-8228-4E48-A99D-526E78DF7313Q33829279-3E7C4068-E3F0-4D12-841E-F65F64B00976Q33847603-338D6872-EB41-4277-BB69-CBF5D578FC4CQ33897625-9E0C7F07-566E-434C-9052-9820A206B4E0Q34041735-8AD1C552-28A4-4F8C-BC41-CDB4D6566252Q34135928-8401671D-CCD3-427C-957A-BBFC186B4508Q34493493-5A110E49-0EBC-48E9-8639-037292E46E27Q34633068-BCA359B1-DB7D-44E5-9E15-2B636A6525D2Q34836491-61DC85ED-C3CD-42F9-AA34-20184443E6FFQ35003631-21D7765E-B7AC-46A3-BBAB-CA9C7B2023D2Q35103355-5AB6AD6A-A5B2-4E40-A3CA-E761FD0C0088Q35170255-81E56315-A11B-40DD-9977-2B6C849EA432Q35290430-51B08CA2-08F4-41CA-9F0B-81F7774AF6B4Q35568485-2F41CAAC-F17A-49E4-906C-CCD5BA592DCBQ35584002-D7E9A5C4-5ACF-42C9-B9D7-A30F1B53E733Q35608002-4D1A6DA6-FD41-4DFC-ACA3-179C810B1B20Q35849774-068CFB6D-6AAC-4548-87D0-D219A81B45F9Q35971034-03291A01-06A3-4E77-84BB-0C845C51F6C8Q36101108-82526CF3-6B94-4669-A624-6680361AF922Q36143838-ACD6C19F-40FD-4756-BEFC-F86F95A6ADFCQ36368864-DBF34C19-453F-4B44-9CBD-CDC2F32163C4Q36609568-671879E5-93F9-4F1C-A4CC-BEE8CE22F112Q36617872-F1E51586-446A-4843-A542-06EB926737D5Q36673860-286FFC93-A029-4D4D-ACDB-9DE776F2FB7EQ36729045-08104085-0537-4CF4-9C68-2CAB966DA024Q36874790-84799DBC-4388-4026-8456-FA882911629DQ36989648-3F3EB590-8954-4152-B43C-3469FA85F3B5Q37098334-86DBE51B-F52A-43A5-AD78-3C2FE8C4AFDEQ37114850-6220075E-D284-486B-B7BA-979873481E5BQ37339650-6EE4D098-8047-466F-96AF-5B675C15012DQ37423919-41C8520C-6157-4BE1-8BB5-3B506A6BCE05Q37516506-CAFCDC75-4019-46D3-B505-07B3139578F4Q37528298-907BF07B-286A-492C-B2C5-DF0C586102ACQ37642455-F41D25AC-8B23-4DE6-A6C7-71C7286C413FQ37975010-C5703D3A-C01F-4F2A-9BD4-4B26E9FE8580Q38088273-A5DAEDC8-F2AA-4C81-ACCA-49089D456EB7
P2860
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Randomized phase II trial of i ...... cell lung cancer: CALGB 30105.
@en
Randomized phase II trial of i ...... horacic conformal radiotherapy
@nl
type
label
Randomized phase II trial of i ...... cell lung cancer: CALGB 30105.
@en
Randomized phase II trial of i ...... horacic conformal radiotherapy
@nl
prefLabel
Randomized phase II trial of i ...... cell lung cancer: CALGB 30105.
@en
Randomized phase II trial of i ...... horacic conformal radiotherapy
@nl
P2093
P921
P356
P1476
Randomized phase II trial of i ...... cell lung cancer: CALGB 30105.
@en
P2093
A William Blackstock
Antonius A Miller
Arthur Sleeper
Gregory A Masters
Jeffrey A Bogart
Julian Rosenman
Mark A Socinski
Mark Green
Michael Munley
P304
P356
10.1200/JCO.2007.14.7371
P407
P577
2008-05-01T00:00:00Z